Literature DB >> 17180062

The ability of Bcl-x(L) and Bcl-2 to prevent apoptosis can be differentially regulated.

A R Gottschalk1, L H Boise, Z N Oltvai, M A Accavitti, S J Korsmeyer, J Quintáns, C B Thompson.   

Abstract

Although expression of Bcl-2 has been shown to prevent apoptosis under many circumstances, there are several systems in which Bcl-2 fails to promote cell survival. We have previously reported that Bcl-2 and Bcl-x(L) display differential ability to protect WEHI-231 cells from multiple inducers of apoptosis. A possible explanation for this paradox was provided by the discovery of Bax. Bax is a Bcl-2-related protein which can inhibit the ability of Bcl-2 to enhance the survival of growth factor-dependent cell lines in the absence of growth factor. Consistent with the possibility that Bcl-2 function in WEHI-231 cells is inhibited by Bax, WEHI-231 cells were found to express a high level of Bax. To directly test the effects of Bax expression on Bcl-x(L) function, FL5.12 cells were transfected with both genes. Although Bax overexpression can inhibit Bcl-2 from prolonging cell survival upon growth factor withdrawal, Bax overexpression did not inhibit Bcl-x(L) from preventing apoptosis in this cell line. Although Bcl-2 and Bcl-x(L) were both found to be able to form heterodimers with Bax, the majority of Bax in both cases was not complexed to a partner. Our data suggest that Bcl-x(L) does not function by simply preventing the formation of Bax homodimers which promote cell death. Instead Bax appears to display selectivity in its ability to inhibit Bcl-2 but not Bcl-x(L) from prolonging survival. Furthermore, our data suggest that the abilities of Bcl-2 and Bcl-x(L) to promote cell survival are not identical and can be independently regulated within a cell. Regulation of a cell's apoptotic threshold is likely to result from a complex set of interactions among Bcl-2 family members and other, as yet uncharacterised, regulators of apoptosis.

Entities:  

Year:  1996        PMID: 17180062

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  6 in total

1.  Distinct sites of action of Bcl-2 and Bcl-xL in the ceramide pathway of apoptosis.

Authors:  W El-Assaad; M El-Sabban; C Awaraji; N Abboushi; G S Dbaibo
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

2.  Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis.

Authors:  J Boer; J Bonten-Surtel; G Grosveld
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

3.  The effect of targeted magnetic nanopaticles on hepatoma and the expression of bcl-2/bax protein.

Authors:  Jianming Wang; Baolai Xiao; Jianwei Zheng; Shengquan Zou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

4.  Evaluation and critical assessment of putative MCL-1 inhibitors.

Authors:  S Varadarajan; M Vogler; M Butterworth; D Dinsdale; L D Walensky; G M Cohen
Journal:  Cell Death Differ       Date:  2013-07-05       Impact factor: 15.828

5.  The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells.

Authors:  J Y Han; Y J Chung; S W Park; J S Kim; M G Rhyu; H K Kim; K S Lee
Journal:  Korean J Intern Med       Date:  1999-01       Impact factor: 2.884

6.  S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.

Authors:  Patrick Casara; James Davidson; Audrey Claperon; Gaëtane Le Toumelin-Braizat; Meike Vogler; Alain Bruno; Maïa Chanrion; Gaëlle Lysiak-Auvity; Thierry Le Diguarher; Jérôme-Benoît Starck; Ijen Chen; Neil Whitehead; Christopher Graham; Natalia Matassova; Pawel Dokurno; Christopher Pedder; Youzhen Wang; Shumei Qiu; Anne-Marie Girard; Emilie Schneider; Fabienne Gravé; Aurélie Studeny; Ghislaine Guasconi; Francesca Rocchetti; Sophie Maïga; Jean-Michel Henlin; Frédéric Colland; Laurence Kraus-Berthier; Steven Le Gouill; Martin J S Dyer; Roderick Hubbard; Mike Wood; Martine Amiot; Gerald M Cohen; John A Hickman; Erick Morris; James Murray; Olivier Geneste
Journal:  Oncotarget       Date:  2018-04-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.